Sepracor Inc. plans to sell European rights to its Lunesta sleeping aid and will include data on the drug's benefits on depression in the application for approval next year.
The company plans to submit its application for European approval of the medicine in the second quarter of 2007, Jonae Barnes, vice president of investor relations, said during a Nov. 8 presentation in London.
Insider says: Big Pharma, form an orderly line (AstraZeneca at the front)!
Source
No comments:
Post a Comment